Serological markers associated with disease activity in patients with rheumatoid arthritis treated with rituximab

Conclusions
C3 and IgM levels may represent potentially useful serological markers of disease activity during rituximab treatment in patients with RA.

Source: Journal of International Medical Research - September 27, 2016 Category: Research Authors: Conigliaro, P., Triggianese, P., Chimenti, M. S., Lucchetti, R., Kroegler, B., Perricone, R. Tags: Immuno-Mediated Diseases and Treatment Immunogenicity Source Type: research